Dec. 22, 2010, 8:57 a.m.
Dec 15, 2010
The PATH Malaria Vaccine Initiative (MVI), pharmaceutical company Merck and New York University's Langone Medical Center on Tuesday announced they were collaborating "to develop a vaccine capable of preventing the malaria parasite from entering the human liver," the Star-Ledger/NJ.com reports (Todd, 12/14). VOA News examines why scientists suspect inhibiting the parasite from entering the liver offers "the best line of defense" against the disease. "With the availability of a first-generation malaria vaccine on the horizon, we are ramping up our efforts to seek out and invest in scientific approaches for malaria vaccines that could potentially be even more effective and protect more people," said Christian Loucq, director of MVI. "We are very pleased that one of the world's largest pharmaceutical companies and a major academic medical center have committed to testing a promising new way to defend children against malaria," he said (12/14).